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The Notch signaling pathway is important for intestinal epithelial stem/progenitor cell self‐renewal and differentiation.[1](#cas13075-bib-0001){ref-type="ref"} Four Notch receptors (Notch 1--4) and five Notch ligands (Delta‐like 1 \[DLL1\], DLL3, DLL4, Jagged‐1 \[JAG1\] and JAG2) have been identified.[2](#cas13075-bib-0002){ref-type="ref"} JAG1, like the other ligands, binds to Notch receptors and induces activation through the cleavage of Notch receptors by γ‐secretase and subsequent release of the Notch intracellular domain (NICD). NICD can translocate to the nucleus, where it forms a complex with a transcriptional regulator and activates transcription of target genes such as the hairy and enhancer of split (HES) gene family.[2](#cas13075-bib-0002){ref-type="ref"}

Accumulating evidence has shown that dysregulation of the Notch pathway has a significant role in the progression of several malignancies. Furthermore, high expression levels of JAG1 are associated with increased progression and metastatic potential, recurrence and poor overall survival (OS) in prostate cancer, breast cancer, glioma, head and neck cancers, and gastric cancer.[3](#cas13075-bib-0003){ref-type="ref"}, [4](#cas13075-bib-0004){ref-type="ref"}, [5](#cas13075-bib-0005){ref-type="ref"}, [6](#cas13075-bib-0006){ref-type="ref"}, [7](#cas13075-bib-0007){ref-type="ref"}, [8](#cas13075-bib-0008){ref-type="ref"}

Additionally, it has been shown that Notch signaling is strongly activated in primary human colorectal cancer (CRC) and has an important role in the initiation and progression of CRC through the regulation of apoptosis, proliferation, angiogenesis and cell migration.[9](#cas13075-bib-0009){ref-type="ref"}, [10](#cas13075-bib-0010){ref-type="ref"}, [11](#cas13075-bib-0011){ref-type="ref"}, [12](#cas13075-bib-0012){ref-type="ref"}, [13](#cas13075-bib-0013){ref-type="ref"}, [14](#cas13075-bib-0014){ref-type="ref"} Recent reports have also indicated that JAG1 mediates the activation of Notch signaling in CRC and induces CRC progression.[15](#cas13075-bib-0015){ref-type="ref"}, [16](#cas13075-bib-0016){ref-type="ref"}, [17](#cas13075-bib-0017){ref-type="ref"}, [18](#cas13075-bib-0018){ref-type="ref"}, [19](#cas13075-bib-0019){ref-type="ref"} Thus, the JAG1‐Notch pathway has been regarded an attractive target for CRC therapy.

Although high expression of JAG1 and the prognostic implications of Notch receptors in cancer cells have been described,[11](#cas13075-bib-0011){ref-type="ref"}, [12](#cas13075-bib-0012){ref-type="ref"}, [13](#cas13075-bib-0013){ref-type="ref"}, [14](#cas13075-bib-0014){ref-type="ref"}, [16](#cas13075-bib-0016){ref-type="ref"}, [17](#cas13075-bib-0017){ref-type="ref"}, [18](#cas13075-bib-0018){ref-type="ref"}, [19](#cas13075-bib-0019){ref-type="ref"}, [20](#cas13075-bib-0020){ref-type="ref"} the prognostic significance of high JAG1 expression in CRC has not been determined. Therefore, we investigated the association of JAG1 protein expression with survival and recurrence in CRC by immunohistochemistry (IHC) using postoperative specimens and survey information on CRC prognosis collected in our research institute. We also examined E‐cadherin expression as a marker of epithelial--mesenchymal transition (EMT) to evaluate a possible relationship between JAG1 and EMT in the prognostic role of these factors in CRC. To our knowledge, the detailed clinical results of this study provide the first report of the poor prognostic implication of high JAG1 expression in CRC patients.

Materials and Methods {#cas13075-sec-0002}
=====================

Patients and specimens {#cas13075-sec-0003}
----------------------

A total of 158 consecutive patients with CRC who underwent surgical resection at the Department of Surgery and Science, Kyushu University Hospital between 1995 and 2002 were analyzed in this study. Histologic diagnosis was based on the World Health Organization Classification of Colorectal Carcinoma.[21](#cas13075-bib-0021){ref-type="ref"} Pathologic staging was performed by the Department of Anatomic Pathology, Pathological Sciences, Kyushu University, Fukuoka, Japan, according to the tumor‐node‐metastasis classification system, as revised in 2002.[22](#cas13075-bib-0022){ref-type="ref"} Written informed consent was obtained from each patient prior to tissue acquisition. All fresh specimens were fixed in 10% formalin and embedded in paraffin. This study was conducted with the approval of the Ethics Committee of Kyushu University Hospital, Fukuoka, Japan in accordance with the Declaration of Helsinki (Approval No. 27‐193).

Immunohistochemistry {#cas13075-sec-0004}
--------------------

Tumor sections were assessed immunohistochemically using rabbit polyclonal antibody against an intracellular region of JAG1 (sc‐8303, 1:200; Santa Cruz Biotechnology, CA, USA), rabbit monoclonal antibody against an extracellular region of JAG1 (2155, 1:100; Cell Signaling Technology, MA, USA) and mouse monoclonal antibody against E‐cadherin (M106, 1:1000; Takara Bio; Kyoto, Japan) with the HRP‐labeled polymer secondary antibody Envision^+^ system (Dako, CA, USA). Briefly, 4‐μm sections were deparaffinized and dehydrated. For antigen retrieval, the specimens were pretreated in an autoclave at 120°C for 15 min in 0.01‐M citrate buffer, pH 6.0. The sections were incubated for 30 min in 0.3% hydrogen peroxidase in absolute methanol to deactivate endogenous peroxidases. After blocking of nonspecific binding with 10% goat serum, the specimens were incubated at 4°C with primary antibodies overnight. After washing with TBS, the sections were incubated with the Envision^+^ system (Dako) for 1 h at room temperature. Color was developed with liquid DAB chromogen in Tris‐buffered saline (pH 7.4) containing hydrogen peroxide. The sections were counterstained with hematoxylin. The immunoreactivity score was determined as described by Allred *et al*.[23](#cas13075-bib-0023){ref-type="ref"} Scoring was performed by the study investigators, including general pathologists. The score for JAG1 was determined by three grades of intensity ("weak" for no or weak staining; "moderate"; or "strong"). The score for E‐cadherin was determined by adding the grades for intensity (1 for no or weak; 2 for moderate; 3 for strong) and the percentage of positive cells (1: 0--1%; 2: 1--10%; 3: 10--33%; 4: 33--66%; and 5: 66--100%).

Statistical analysis {#cas13075-sec-0005}
--------------------

All statistical calculations were performed using JMP Pro 10 statistical software (SAS Institute Japan, Tokyo, Japan). Relationships among the clinicopathologic factors and JAG1 and E‐cadherin staining were analyzed using χ^2^‐tests. Survival curves were plotted using the Kaplan--Meier method, and the log‐rank test was used to determine associations between individual variables and survival. OS and relapse‐free survival (RFS) were evaluated using the univariate or multivariate Cox proportional hazard model. Recurrence rate was evaluated using the multivariate logistic regression model. Differences were considered significant at *P* \< 0.05.

Additional experimental information {#cas13075-sec-0006}
-----------------------------------

Additional information is available in the Supporting informations.

Results {#cas13075-sec-0007}
=======

JAG1 immunohistochemistry {#cas13075-sec-0008}
-------------------------

Antibody against the intracellular region of JAG1 was used for immunohistochemical staining of CRC specimens. This antibody was relatively selective for JAG1 protein and had appropriate characteristics for analyzing the prognostic significance of JAG1 expression in the cancerous tissue and the endothelium by IHC, as shown in the supporting informations (Figs S1,S2).

Immunohistochemical analysis indicated that JAG1 was expressed by cancer cells and the endothelium (Fig. [1](#cas13075-fig-0001){ref-type="fig"}). Weak (jcIHC‐W), moderate (jcIHC‐M) and strong (jcIHC‐S) staining of cancerous tissues was detected in 51 (32%), 57 (36%) and 50 (32%) samples, respectively (Fig. [1](#cas13075-fig-0001){ref-type="fig"}, Table [1](#cas13075-tbl-0001){ref-type="table-wrap"}). Weak (jeIHC‐W), moderate (jeIHC‐M) and strong (jeIHC‐S) staining of endothelium was detected in 61 (39%), 54 (34%) and 43 (27%) samples, respectively (Fig. [1](#cas13075-fig-0001){ref-type="fig"}, Table [1](#cas13075-tbl-0001){ref-type="table-wrap"}).

![Representative immunohistochemical staining of JAG1 expression in human colorectal cancer tissues (original magnification ×100, scale bars represent 0.25 mm). (a) Example of cancer and endothelium tissue with weak intensity of staining (jcIHC‐W, jeIHC‐W). (b) Example of cancer and endothelium with moderate intensity of staining (jcIHC‐M, jeIHC‐M). (c) Example of cancer and endothelium with moderate and strong intensity of staining, respectively (jcIHC‐M, jeIHC‐S). (d) Example of cancer and endothelium with strong intensity of staining (jcIHC‐S, jeIHC‐S). (e) Example of poorly differentiated carcinoma with a strong intensity of staining. Representative each five regions in cancer or endothelium were indicated by open or filled arrow‐heads, respectively.](CAS-107-1705-g001){#cas13075-fig-0001}

###### 

Association between clinical characteristics and JAG1 expression in cancer cells and endothelium

  Characteristics             JAG1 (cancer cells)   *P*‐value     JAG1 (endothelium)   *P‐*value                                                                                       
  --------------------------- --------------------- ------------- -------------------- --------------------------------------------------- ------------------- ------------- --------- ---------------------------------------------------
  **Total**                   51 (32)               57 (36)       50 (32)                                                                  61 (39)             54 (34)       43 (27)   
  **Sex**                                                                              0.352                                                                                           0.877
  Male                        31 (61)               36 (63)       25 (50)              36 (59)                                             30 (56)             26 (60)                 
  Female                      20 (39)               21 (37)       25 (50)              25 (41)                                             24 (44)             17 (40)                 
  **Age (years)**                                                                      NS                                                                                              NS
  Mean ± SD                   64.7 ± 10.8           64.6 ± 11.8   62.1 ± 13.9          63.0 ± 12.3                                         63.1 ± 10.1         65.9 ± 14.3             
  **Histologic type**                                                                  0.031[\*](#cas13075-note-0002){ref-type="fn"}                                                   0.495
  Well differentiated         38 (79)               34 (61)       26 (55)              41 (71)                                             32 (62)             25 (61)                 
  Moderate/Poorly             10 (21)               22 (39)       21 (45)              17 (29)                                             20 (38)             16 (39)                 
  Others                      3                     1             3                    3                                                   2                   2                       
  **T stage**                                                                          0.003[\*\*](#cas13075-note-0002){ref-type="fn"}                                                 0.080
  T1                          14 (27)               8 (14)        2 (4)                15 (25)                                             6 (11)              3 (7)                   
  T2                          6 (12)                7 (12)        8 (16)               5 (8)                                               6 (11)              10 (23)                 
  T3                          29 (57)               31 (55)       26 (53)              32 (54)                                             32 (59)             22 (51)                 
  T4                          2 (4)                 11 (19)       13 (27)              8 (13)                                              10 (19)             8 (19)                  
  Unknown                                                         1                    1                                                                                               
  **Lymph node metastasis**                                                            0.242                                                                                           0.035[\*](#cas13075-note-0002){ref-type="fn"}
  Negative                    33 (65)               28 (49)       26 (53)              40 (67)                                             23 (43)             24 (56)                 
  Positive                    18 (35)               29 (51)       23 (47)              20 (33)                                             31 (57)             19 (44)                 
  Unknown                                                         1                    1                                                                                               
  **Stage of tumor**                                                                   0.126                                                                                           0.114
  0--I                        18 (35)               12 (21)       7 (14)               20 (33)                                             6 (11)              11 (25)                 
  II                          12 (24)               14 (25)       15 (30)              16 (26)                                             13 (24)             12 (28)                 
  III                         15 (29)               23 (40)       15 (30)              17 (28)                                             22 (41)             14 (33)                 
  IV                          6 (12)                8 (14)        13 (26)              8 (13)                                              13 (24)             6 (14)                  
  **Lymphatic invasion**                                                               0.136                                                                                           0.436
  Negative                    39 (76)               34 (60)       31 (62)              43 (70)                                             32 (59)             29 (67)                 
  Positive                    12 (24)               23 (40)       19 (38)              18 (30)                                             22 (41)             14 (33)                 
  **Venous invasion**                                                                  0.818                                                                                           0.039[\*](#cas13075-note-0002){ref-type="fn"}
  Negative                    32 (63)               33 (58)       27 (54)              39 (64)                                             24 (44)             29 (67)                 
  Positive                    19 (37)               24 (42)       23 (46)              22 (36)                                             30 (56)             14 (33)                 
  **JAG1 (Endothelium)**                                                               \<0.001[\*\*](#cas13075-note-0002){ref-type="fn"}   **JAG1 (Cancer)**                           \<0.001[\*\*](#cas13075-note-0002){ref-type="fn"}
  Weak                        35 (69)               17 (30)       9 (18)                                                                   35 (57)             14 (26)       2 (5)     
  Moderate                    14 (27)               24 (42)       16 (32)                                                                  17 (28)             24 (44)       16 (37)   
  Strong                      2 (4)                 16 (28)       25 (50)                                                                  9 (15)              16 (30)       25 (58)   
  **Recurrence**                                                                       0.009[\*\*](#cas13075-note-0002){ref-type="fn"}                                                 0.180
  Absent                      45 (90)               42 (76)       29 (64)              47 (78)                                             42 (84)             27 (68)                 
  Present                     5 (10)                13 (24)       16 (36)              13 (22)                                             8 (16)              13 (32)                 
  Unknown                     1                     2             5                    1                                                   4                   3                       

χ^2^‐test: \**P *\< 0.05, \*\**P *\< 0.01. Each value is presented as number (%) of specimens. NS, not significant; SD, standard deviation.
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Correlation of JAG1 expression in cancer cells or endothelium with clinicopathologic characteristics and recurrence {#cas13075-sec-0009}
-------------------------------------------------------------------------------------------------------------------

The correlation between JAG1 expression and clinicopathologic characteristics is shown in Table [1](#cas13075-tbl-0001){ref-type="table-wrap"}. JAG1 expression in cancer cells was correlated with histologic type (*P* = 0.031) and T stage (*P* = 0.003). JAG1 expression in cancer cells was also significantly associated with JAG1 expression in endothelium (*P* \< 0.001) and rate of recurrence (*P* = 0.009). Moreover, JAG1 expression in endothelium was correlated with lymph node metastasis (*P* = 0.035) and venous invasion (*P* = 0.039). Moderate intensity of staining in the endothelium tended to be associated with poorer characteristics than the other staining groups.

Analysis of the association between JAG1 expression and survival outcome {#cas13075-sec-0010}
------------------------------------------------------------------------

The association between JAG1 expression in cancer cells and OS was evaluated in all patients (Fig. [2](#cas13075-fig-0002){ref-type="fig"}a). JAG1 expression was significantly associated with OS (*P* = 0.006). Evaluation of the association between JAG1 expression and RFS in 131 patients with stage 0--III CRC (ST_0‐III) showed that JAG1 expression was also significantly associated with RFS (Fig. [2](#cas13075-fig-0002){ref-type="fig"}b; *P* = 0.010). Analysis of the prognostic significance of JAG1 expression as indicated by the 5‐year survival rate calculated by Kaplan--Meier estimates and hazard ratios determined using the Cox proportional hazard model revealed that higher expression of JAG1 is associated with a poorer survival rate and larger hazard ratio (Fig. S3).

![Prognostic significance of JAG1 expression in cancer cells by analysis of Kaplan--Meier estimates. (a) Kaplan--Meier estimates of 10‐year overall survival (OS) in all CRC patients and (b) 5‐year recurrence‐free survival (RFS) in patients except for Stage IV CRC according to staining intensity. *Mod* indicates moderate.](CAS-107-1705-g002){#cas13075-fig-0002}

In univariate analysis of OS in all patients and for RFS in the ST_0‐III subgroup, JAG1 expression was significantly correlated with both OS and RFS (Table [2](#cas13075-tbl-0002){ref-type="table-wrap"}). In multivariate analysis, JAG1 expression, histologic type and lymphatic invasion showed independent association with OS and RFS (Table [2](#cas13075-tbl-0002){ref-type="table-wrap"}). Univariate analysis of the rate of recurrence in all patients using the logistic model (Table [2](#cas13075-tbl-0002){ref-type="table-wrap"}) revealed a significant correlation of JAG1 expression with recurrence. Multivariate analysis showed that tumor stage and JAG1 expression were independently associated with recurrence (Table [2](#cas13075-tbl-0002){ref-type="table-wrap"}).

###### 

Univariate and multivariate analysis of factors associated with overall survival or relapse‐free survival

  Characteristics                                                    Parameters           Univariate analysis   Multivariate analysis                                                                            
  ------------------------------------------------------------------ -------------------- --------------------- ----------------------- --------------------------------------------------- ------ ------------- ---------------------------------------------------
  **Overall survival (All patients, Cox model)**                                                                                                                                                                 
  Sex                                                                M *vs* F             1.37                  0.73--2.54              0.316                                               1.35   0.70--2.57    0.366
  Age                                                                \< 65 *vs* ≥65       0.96                  0.52--1.78              0.906                                               0.99   0.51--1.93    0.980
  Histologic type                                                    Well *vs* Others     4.51                  2.38--9.00              \<0.001[\*\*](#cas13075-note-0003){ref-type="fn"}   2.59   1.19--5.94    0.016[\*](#cas13075-note-0003){ref-type="fn"}
  T stage                                                            T1,2 *vs* T3,4       3.91                  1.56--13.07             0.002[\*\*](#cas13075-note-0003){ref-type="fn"}     1.47   0.51--5.31    0.497
  Lymph node metastasis                                              − *vs* +             3.93                  2.02--8.23              \<0.001[\*\*](#cas13075-note-0003){ref-type="fn"}   2.04   0.61--12.68   0.283
  Stage of tumor                                                     0/I/II *vs* III/IV   4.08                  2.03--9.08              \<0.001[\*\*](#cas13075-note-0003){ref-type="fn"}   1.02   0.14--4.31    0.980
  Lymphatic invasion                                                 − *vs* +             5.09                  2.72--9.88              \<0.001[\*\*](#cas13075-note-0003){ref-type="fn"}   3.88   1.81--8.63    \<0.001[\*\*](#cas13075-note-0003){ref-type="fn"}
  Venous invasion                                                    − *vs* +             2.18                  1.18--4.09              0.013[\*](#cas13075-note-0003){ref-type="fn"}       1.69   0.78--3.65    0.184
  JAG1 (Cancer)                                                      W *vs* Mod/S         3.99                  1.71--11.62             \<0.001[\*\*](#cas13075-note-0003){ref-type="fn"}   2.62   1.10--7.74    0.027[\*](#cas13075-note-0003){ref-type="fn"}
  **Relapse‐free survival (Patients besides Stage IV, Cox model)**                                                                                                                                               
  Sex                                                                M *vs* F             1.58                  0.78--3.13              0.226                                               1.21   0.54--2.63    0.643
  Age                                                                \<65 *vs* ≥65        1.66                  0.83--3.42              0.138                                               2.10   0.99--4.62    0.055
  Histologic type                                                    Well *vs* Others     4.74                  2.34--10.15             \<0.001[\*\*](#cas13075-note-0003){ref-type="fn"}   2.71   1.09--6.91    0.032[\*](#cas13075-note-0003){ref-type="fn"}
  T stage                                                            T1,2 *vs* T3,4       2.40                  1.06--6.44              0.035[\*](#cas13075-note-0003){ref-type="fn"}       0.92   0.33--2.77    0.870
  Lymph node metastasis                                              − *vs* +             3.04                  1.52--6.37              0.002[\*\*](#cas13075-note-0003){ref-type="fn"}     1.60   0.25--31.32   0.660
  Stage of tumor                                                     0/I/II *vs* III      3.16                  1.56--6.76              0.001[\*\*](#cas13075-note-0003){ref-type="fn"}     1.35   0.07--8.07    0.793
  Lymphatic invasion                                                 − *vs* +             4.56                  2.29--9.20              \<0.001[\*\*](#cas13075-note-0003){ref-type="fn"}   4.47   1.76--11.57   0.002[\*\*](#cas13075-note-0003){ref-type="fn"}
  Venous invasion                                                    − *vs* +             2.07                  1.03--4.12              0.033[\*](#cas13075-note-0003){ref-type="fn"}       0.51   0.19--1.37    0.184
  JAG1 (Cancer)                                                      W *vs* Mod/S         2.38                  1.17--4.74              0.017[\*](#cas13075-note-0003){ref-type="fn"}       2.65   1.16--5.95    0.021[\*](#cas13075-note-0003){ref-type="fn"}
  **Recurrence (All patients, Logistic model)**                                                                                                                                                                  
  Sex                                                                M *vs* F                                                           0.838                                                                    0.628
  Age                                                                \<65 *vs* ≥65                                                      0.369                                                                    0.080
  Histologic type                                                    Well *vs* Others                                                   0.003[\*\*](#cas13075-note-0003){ref-type="fn"}                          0.082
  T stage                                                            T1,2 *vs* T3,4                                                     0.272                                                                    0.354
  Lymph node metastasis                                              − *vs* +                                                           0.006[\*\*](#cas13075-note-0003){ref-type="fn"}                          0.712
  Stage of tumor                                                     0/I/II *vs* III/IV                                                 0.005[\*\*](#cas13075-note-0003){ref-type="fn"}                          0.035[\*](#cas13075-note-0003){ref-type="fn"}
  Lymphatic invasion                                                 − *vs* +                                                           0.031[\*](#cas13075-note-0003){ref-type="fn"}                            0.471
  Venous invasion                                                    − *vs* +                                                           0.191                                                                    0.846
  JAG1 (Cancer)                                                      W/Mod *vs* S                                                       0.011[\*](#cas13075-note-0003){ref-type="fn"}                            0.033[\*](#cas13075-note-0003){ref-type="fn"}

\**P *\< 0.05, \*\**P *\< 0.01. CI, confidence interval; F, female; HR, hazard ratio; M, male; Mod, moderate; S, strong; W, weak.
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The association between JAG1 expression in endothelium and OS or RFS was also analyzed (Fig. S4a,b). The 5‐year survival rate calculated by the Kaplan--Meier estimate is shown in Figure S4c and prognostic analysis of JAG1 expression by the Cox proportional hazard model is shown in Figure S4d. High expression of JAG1 in endothelium was more strongly associated with RFS than with OS.

Analysis of the association between JAG1 and E‐cadherin expression {#cas13075-sec-0011}
------------------------------------------------------------------

To investigate whether JAG1 expression is associated with the transition between epithelial and mesenchymal characteristics, E‐cadherin expression was analyzed as an epithelial marker by IHC (Fig. S5). E‐cadherin expression was categorized by staining intensity (eIHC‐In1--3) or the proportion of positive cells (eIHC‐Pr1--5), as shown in Figure S5 and Table [3](#cas13075-tbl-0003){ref-type="table-wrap"}. High JAG1 expression (jcIHC‐S *versus* jcIHC‐W/M) was significantly correlated with low E‐cadherin expression in subgroup stratification by proportion (eIHC‐Pr1‐3 *versus* eIHC‐Pr4/5) (Table [3](#cas13075-tbl-0003){ref-type="table-wrap"}, P = 0.023).

###### 

Associations between E‐cadherin expression and clinical characteristics or JAG1 expression in cancer cells

  Characteristics             E‐cadherin (Intensity)   *P* value   E‐cadherin (Proportion)                             *P* value              
  --------------------------- ------------------------ ----------- --------------------------------------------------- ----------- ---------- ---------------------------------------------------
  **Total**                   39 (25)                  119 (75)                                                        44 (28)     114 (72)   
  **Sex**                                                                                                                                     
  Male                        22 (56)                  70 (59)     0.791                                               18 (41)     48 (42)    0.891
  Female                      17 (44)                  49 (41)     26 (59)                                             66 (58)                
  **Age (years)**                                                                                                                             
  \<65                        18 (46)                  63 (53)     0.462                                               24 (55)     57 (50)    0.608
  ≥65                         21 (54)                  56 (47)     20 (45)                                             57 (50)                
  **Histologic type**                                                                                                                         
  Well differentiated         17 (44)                  81 (68)     0.007[\*\*](#cas13075-note-0004){ref-type="fn"}     20 (45)     78 (68)    0.008[\*\*](#cas13075-note-0004){ref-type="fn"}
  Others                      22 (56)                  38 (32)     24 (55)                                             36 (32)                
  **T stage**                                                                                                                                 
  T1, 2                       1 (3)                    44 (37)     \<0.001[\*\*](#cas13075-note-0004){ref-type="fn"}   4 (9)       41 (36)    \<0.001[\*\*](#cas13075-note-0004){ref-type="fn"}
  T3, 4                       38 (97)                  74 (63)     40 (91)                                             72 (64)                
  Unknown                                              1                                                               1                      
  **Lymph node metastasis**                                                                                                                   
  Negative                    15 (38)                  72 (61)     0.014[\*](#cas13075-note-0004){ref-type="fn"}       19 (43)     68 (60)    0.055
  Positive                    24 (62)                  46 (39)     25 (57)                                             45 (40)                
  Unknown                                              1                                                               1                      
  **Stage of tumor**                                                                                                                          
  0/I/II                      10 (26)                  68 (57)     \<0.001[\*\*](#cas13075-note-0004){ref-type="fn"}   13 (30)     65 (57)    0.002[\*\*](#cas13075-note-0004){ref-type="fn"}
  III/IV                      29 (74)                  51 (43)     31 (70)                                             49 (43)                
  **Lymphatic invasion**                                                                                                                      
  Negative                    18 (46)                  86 (72)     0.003[\*\*](#cas13075-note-0004){ref-type="fn"}     23 (52)     81 (71)    0.028[\*](#cas13075-note-0004){ref-type="fn"}
  Positive                    21 (54)                  33 (28)     21 (48)                                             33 (29)                
  **Venous invasion**                                                                                                                         
  Negative                    15 (38)                  77 (65)     0.004[\*\*](#cas13075-note-0004){ref-type="fn"}     21 (48)     71 (62)    0.100
  Positive                    34 (62)                  42 (35)     23 (52)                                             43 (38)                
  **JAG1 (Cancer)**                                                                                                                           
  Weak                        11 (28)                  40 (34)     0.527                                               14 (32)     37 (32)    0.939
  Moderate/Strong             28 (72)                  79 (66)                                                         30 (68)     77 (68)    
  Weak/moderate               26 (67)                  82 (69)     0.795                                               24 (55)     84 (74)    0.023[\*](#cas13075-note-0004){ref-type="fn"}
  Strong                      13 (33)                  37 (31)                                                         20 (45)     30 (26)    

χ^2^‐test: \**P *\< 0.05, \*\**P *\< 0.01. Each value is presented as number (%) of specimens.
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Analysis of JAG1 expression in patient samples stratified by E‐cadherin expression {#cas13075-sec-0012}
----------------------------------------------------------------------------------

A significant poor prognosis of low E‐cadherin expression for OS was detected by log‐rank test in the analysis according to staining intensity of 1 *vs* 2/3 (Fig. S6a, *P* = 0.038). In this stratification, no correlation between JAG1 and E‐cadherin expression was detected (Table [3](#cas13075-tbl-0003){ref-type="table-wrap"}); therefore, an additional prognostic impact of combined JAG1 and E‐cadherin expression was expected. To investigate the significance of JAG1 expression on prognosis in samples stratified by intensity of E‐cadherin staining, patients were divided into six groups as follows: (i) jcIHC‐W/eIHC‐In2/3; (ii) jcIHC‐M/eIHC‐In2/3; (iii) jcIHC‐S/eIHC‐In2/3; (iv) jcIHC‐W/eIHC‐In1; (v) jcIHC‐M/eIHC‐In1; and (vi) jcIHC‐S/eIHC‐In1 (Table [4](#cas13075-tbl-0004){ref-type="table-wrap"}). The *P*‐value of the log‐rank test for OS and RFS was 0.011 and 0.001, respectively (Fig. [3](#cas13075-fig-0003){ref-type="fig"}a,b). OS and RFS in jcIHC‐M/eIHC‐In2/3, jcIHC‐S/eIHC‐In2/3, jcIHC‐M/eIHC‐In1 and jcIHC‐S/eIHC‐In1 groups were significantly shorter than those of the jcIHC‐W/eIHC‐In2/3 group (Fig. [3](#cas13075-fig-0003){ref-type="fig"}a--d). Specifically, the jcIHC‐S/eIHC‐In1 group showed the poorest outcome of all groups: 3‐year OS = 34.9% (HR = 10.08, 95% CI = 2.64--47.97, *P* = 0.001 \[*vs* jcIHC‐W/eIHC‐In2/3\]); 3‐year RFS = 33.3% (HR = 8.27, 95% CI = 2.49--31.67, *P* = 0.001 \[*vs* jcIHC‐W/eIHC‐In2/3\]). The relationship between JAG1 expression and RFS was notable in the group with moderate or strong intensity of E‐cadherin staining (eIHC‐In2‐3). Namely, the 3‐year RFS rate in jcIHC‐S/eIHC‐In2/3 (45.6%) was much lower than that in jcIHC‐M/eIHC‐In2/3 (68%), whereas the 3‐year OS rate in jcIHC‐S/eIHC‐In2/3 (74.3%) was almost the same as that for jcIHC‐M/eIHC‐In2/3 (71.9%). This may indicate that high JAG1 expression is associated with shorter duration of recurrence rather than survival in the group with moderate or strong intensity of E‐cadherin staining (eIHC‐In2/3).

###### 

JAG1 expression in cancer cells stratified by E‐cadherin expression (based on intensity of staining) and correlation with clinicopathologic characteristics, JAG1 expression in endothelium, and KRAS status

  Characteristics             E‐cadherin intensity (1)   *P*‐value   E‐cadherin intensity (2/3)   *P*‐value                                                                       
  --------------------------- -------------------------- ----------- ---------------------------- ------------------------------------------------- --------- --------- --------- ---------------------------------------------------
  **Total**                   11 (28)                    15 (38)     13 (33)                                                                        40 (34)   42 (35)   37 (31)   
  **Sex**                                                                                         0.899                                                                           0.149
  Male                        6 (55)                     8 (53)      8 (62)                       25 (62)                                           28 (67)   17 (46)             
  Female                      5 (45)                     7 (47)      5 (38)                       15 (38)                                           14 (33)   20 (54)             
  **Age (years)**                                                                                 0.321                                                                           0.683
  \<65                        3 (27)                     8 (53)      7 (54)                       22 (55)                                           20 (48)   21 (57)             
  ≥65                         8 (73)                     7 (47)      6 (46)                       18 (45)                                           22 (52)   16 (43)             
  **Histologic type**                                                                             0.475                                                                           0.045[\*](#cas13075-note-0005){ref-type="fn"}
  Well differentiated         5 (45)                     8 (53)      4 (31)                       33 (83)                                           26 (62)   22 (59)             
  Others                      6 (55)                     7 (47)      9 (69)                       7 (17)                                            16 (38)   15 (41)             
  **T stage**                                                                                     0.377                                                                           0.110
  T1, T2                      0 (0)                      1 (7)       0 (0)                        20 (50)                                           14 (33)   10 (28)             
  T3, T4                      11 (100)                   14 (93)     13 (100)                     20 (50)                                           28 (67)   26 (72)             
  Unknown                                                                                                                                                     1                   
  **Lymph node metastasis**                                                                       0.480                                                                           0.348
  Negative                    5 (45)                     4 (27)      6 (46)                       28 (70)                                           24 (57)   20 (56)             
  Positive                    6 (55)                     11 (73)     7 (54)                       12 (30)                                           18 (43)   16 (44)             
  Unknown                                                                                                                                                     1                   
  **Stage of tumor**                                                                              0.800                                                                           0.226
  0/I/II                      3 (27)                     3 (20)      4 (31)                       27 (68)                                           23 (55)   18 (49)             
  III/IV                      8 (73)                     12 (80)     9 (69)                       13 (32)                                           19 (45)   19 (51)             
  **Lymphatic invasion**                                                                          0.998                                                                           0.070
  Negative                    5 (45)                     7 (47)      6 (46)                       34 (85)                                           27 (64)   25 (68)             
  Positive                    6 (55)                     8 (53)      7 (54)                       6 (15)                                            15 (36)   12 (32)             
  **Venous invasion**                                                                             0.822                                                                           0.724
  Negative                    5 (45)                     5 (33)      5 (38)                       27 (68)                                           28 (67)   22 (59)             
  Positive                    6 (55)                     10 (67)     8 (62)                       13 (32)                                           14 (33)   15 (41)             
  **JAG1 (Endothelium)**                                                                          0.052                                                                           \<0.001[\*\*](#cas13075-note-0005){ref-type="fn"}
  Weak/moderate               10 (91)                    10 (67)     6 (46)                       39 (98)                                           31 (74)   19 (51)             
  Strong                      1 (9)                      5 (33)      7 (54)                       1 (2)                                             11 (26)   18 (49)             
  **KRAS status**                                                                                 0.527                                                                           0.048[\*](#cas13075-note-0005){ref-type="fn"}
  Total                       6                          8           9                            12                                                22        21                  
  Wild type                   3 (50)                     5 (63)      7 (78)                       10 (83)                                           17 (77)   11 (52)             
  Mutant                      3 (50)                     3 (37)      2 (22)                       2 (17)                                            5 (23)    10 (48)             
  **BRAF status**                                                                                 0.111                                                                           0.863
  Total                       5                          8           9                            11                                                22        21                  
  Wild type                   4 (80)                     8 (100)     6 (67)                       10 (91)                                           21 (95)   20 (95)             
  Mutant                      1 (20)                     0 (0)       3 (33)                       1 (9)                                             1 (5)     1 (5)               
  **MSI status**                                                                                  0.007[\*\*](#cas13075-note-0005){ref-type="fn"}                                 0.977
  Total                       10                         12          11                           22                                                33        29                  
  MSS or MSI‐L                10 (100)                   12 (100)    7 (64)                       19 (86)                                           29 (88)   25 (86)             
  MSI‐H                       0 (0)                      0 (0)       4 (36)                       3 (14)                                            4 (12)    4 (14)              

Each value is presented as number (%) of specimens. χ^2^‐test: \**P *\< 0.05, \*\**P *\< 0.01.
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![Prognostic significance of JAG1 expression in cancer cells stratified by E‐cadherin expression (based on intensity of staining) shown by analysis of Kaplan--Meier estimates and Cox proportional hazards model. (a, b) Kaplan--Meier estimate of 5‐year OS (a) and 5‐year RFS (b) in CRC patients according to staining intensity of JAG1 expression in cancer cells stratified by E‐cadherin expression. jcIHC‐W, ‐M, ‐S indicate weak, moderate, and strong intensity of staining of JAG1 expression in cancer cells, respectively. eIHC‐In2/3 and eIHC‐In1 indicate staining intensity of 2/3 and 1 for E‐cadherin expression, respectively. (c) 3‐year survival rate calculated by analysis of the Kaplan--Meier estimates shown in (a) and (b). (d) Hazard ratio (HR) and 95 % confidence interval (CI) of JAG1 and E‐cadherin expression analyzed by Cox proportional hazards model *versus* jcIHC‐W/eIHC‐In2/3 group.](CAS-107-1705-g003){#cas13075-fig-0003}

The correlation of JAG1 expression in cancer cells stratified by E‐cadherin expression with clinicopathologic characteristics, JAG1 expression in endothelium, KRAS, BRAF and MSI status was evaluated (Tables [4](#cas13075-tbl-0004){ref-type="table-wrap"},S1 and Fig. S7). Because of the retrospective analysis, data on KRAS, BRAF and MSI status were available for only 78, 76 and 117 specimens of the 158 CRC patients, respectively. JAG1 expression in cancer cells stratified as high intensity of E‐cadherin staining or large proportion of E‐cadherin expression (eIHC‐In2/3 or eIHC‐Pr4/5) was significantly correlated with histologic type (Tables [4](#cas13075-tbl-0004){ref-type="table-wrap"},S1). A higher rate of KRAS mutation was observed in the jcIHC‐S/eIHC‐In2/3 group (48%) compared with the other groups (17% for jcIHC‐W/eIHC‐In2/3 and 23% for jcIHC‐M/eIHC‐In2/3) (Table [4](#cas13075-tbl-0004){ref-type="table-wrap"}, Fig. S7). A significant correlation between JAG1 expression and KRAS status (*P* = 0.037, data not shown) was also observed in the group with eIHC‐Pr5 in stratification by eIHC‐Pr1‐4 (*n* = 79) *versus* eIHC‐Pr5 (*n* = 79) based on the proportion of E‐cadherin expression. These results suggested that one of the mechanisms for high JAG1 expression in CRC was the enhancement of KRAS and its downstream pathway. There was not a significant correlation between JAG1 expression and BRAF or MSI status in the group stratified as strong and moderate intensity of E‐cadherin staining (eIHC‐In2/3). In contrast, in the group of the other stratification in E‐cadherin (eIHC‐In1), strong intensity of JAG1 staining seemed to associate with MSI or BRAF status. However, we could not determine whether these associations for MSI or BRAF status were really significant because the sample size was small.

Mechanism of increasing JAG1 expression and JAG1‐dependent promotion of epithelial--mesenchymal transition and proliferation in a colon cancer cell line {#cas13075-sec-0013}
--------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate whether the KRAS‐MEK‐MAP kinase pathway regulates JAG1 expression and the transition between epithelial and mesenchymal status, the effect of the MEK inhibitor PD325901 was examined in the HCT‐116 colon cancer cell line. Treatment with MEK inhibitor decreased expression of JAG1 and the mesenchymal marker SNAIL (Fig. [4](#cas13075-fig-0004){ref-type="fig"}a,b). Conversely, E‐cadherin expression was increased after inhibition of MEK (Fig. [4](#cas13075-fig-0004){ref-type="fig"}a,b). The effect of the MEK inhibitor PD325901 on JAG1 expression and transition toward mesenchymal phenotype was also investigated by western blotting in the HCT‐116 (KRAS G13D) and Caco‐2 (KRAS wild) colon cancer cell lines (Fig. S8). HCT‐116 cells have a lower level of E‐cadherin and a higher level of JAG1, SNAIL, phosphorylated ERK1/2 in the control condition than in Caco‐2 cells. Inhibition of MEK kinase lead to suppression of phosphorylated ERK1/2, JAG1 and SNAIL level in HCT‐116. Conversely, increasing E‐cadherin expression was observed by inhibition of MEK in HCT‐116. In contrast, there was no or little change for JAG1, E‐cadherin and SNAIL expression with inhibition of MEK in Caco‐2.

![Mechanisms of regulation of JAG1 expression based on *in vitro* study. (a) The effect of inhibition of RAS‐MEK‐MAP kinase pathway on JAG1 expression and induction of EMT‐like phenotype was examined using the MEK inhibitor PD325901 in the colon cancer cell line HCT‐116. In the left panel, blue staining indicates the nucleus and green staining indicates JAG1 protein. In the middle panel, blue staining indicates the nucleus and red staining indicates E‐cadherin protein. In the right panel, blue, green, and red staining indicate the nucleus, SNAIL, and JAG1 protein, respectively. Scale bars represent 50 µm. (b) Fluorescence intensity of JAG1, Snail, and E‐cadherin was analyzed. Data are presented as mean ± SD of 20 fields of view. \*, *P* \< 0.05, Student\'s *t*‐test. (c) Effects of GSK3β inhibitor on JAG1 protein expression and EMT‐like phenotype. JAG1, E‐cadherin, and SNAIL protein expression was analyzed by western blotting.](CAS-107-1705-g004){#cas13075-fig-0004}

We also detected the positive regulation of JAG1 expression and the EMT resulting from Wnt‐β catenin pathway activation by the GSK3β inhibitor, CHIR‐99021, in HCT‐116 cells. Namely, treatment with CHIR‐99021 increased JAG1 and SNAIL expression and decreased E‐cadherin expression (Fig. [4](#cas13075-fig-0004){ref-type="fig"}c).

The effect of *JAG1* gene silencing on EMT in the colon cancer cell line was investigated using siRNA for *JAG1* (siJAG1). Western blot (Fig. [5](#cas13075-fig-0005){ref-type="fig"}a), qRT‐PCR (Fig. [5](#cas13075-fig-0005){ref-type="fig"}b) and immunofluorescence (Fig. S9) analyses indicated that siJAG1 treatment increased expression of E‐cadherin protein/mRNA, decreased expression of Snail protein and decreased expression of the mesenchymal marker vimentin mRNA compared with control non‐targeting siRNA (siNON) treatment. These results suggested that the colon cancer cell line transited into a more epithelial and less mesenchymal phenotype upon *JAG1* gene silencing.

![Effect of *JAG1* gene silencing on proliferation and epithelial mesenchymal transition (EMT)‐like phenotype based on *in vitro* study. (a, b) Effect of small interfering RNA for JAG1 (siJAG1) on JAG1 expression and EMT‐like phenotype. E‐cadherin and SNAIL protein expression (a) or E‐cadherin (*CDH1*) and vimentin (*VIM*) mRNA expression (b) were analyzed by western blotting and qRT‐PCR respectively. Non‐targeting siRNA (siNON) was used as a negative control. Expression levels of mRNA are indicated relative to expression with siNON treatment. Data are mean ± SD of nine wells. (c) Effect of siJAG1 on *JAG1* and *HES1* mRNA expression in *p53* ^*−/−*^ and wild type (Wt) HCT‐116 cells. mRNA expression was presented as a ratio relative to expression in Wt cells treated with siNON in the left two panels. *JAG1* mRNA expression in Wt or *p53* ^*−/−*^ cells treated with siJAG1 was also presented as a ratio relative to expression in Wt or *p53‐/‐* cells treated with siNON in the right panels. Data are mean ± SD of nine wells. (d) Effect of siJAG1 on JAG1 protein expression in *p53* ^*−/−*^ and Wt cells analyzed by western blotting. (e) Effect of siJAG1 on cell growth in *p53* ^*−/−*^ and Wt cells. siJAG1 treatment was initiated 2 days after plating. Data are presented as mean ± SD of six wells for each time point (result from three independent experiments). Statistical analysis was performed by Student\'s *t*‐test. \* or ^\#^, *P* \< 0.05.](CAS-107-1705-g005){#cas13075-fig-0005}

We also examined the effect of siJAG1 on proliferation of HCT‐116 cells and explored the possibility of crosstalk between the JAG1‐Notch pathway and p53‐related signaling by investigating the effects in HCT‐116 *p53* ^*−/−*^ cells (p53KO). siJAG1 at the concentration of 30 nM decreased *JAG1* mRNA levels by more than 80% compared with siNON in both wild type (Wt) and p53KO cells (Fig. [5](#cas13075-fig-0005){ref-type="fig"}c). mRNA expression of *HES1*, one of the Notch signal target genes, was also decreased, suggesting suppression of intracellular Notch signaling (Fig. [5](#cas13075-fig-0005){ref-type="fig"}c). *JAG1* and *HES1* mRNA expression was significantly lower in p53KO than in Wt cells (Fig. [5](#cas13075-fig-0005){ref-type="fig"}c). JAG1 protein level was also suppressed by siJAG1 compared with siNON treatment (Fig. [5](#cas13075-fig-0005){ref-type="fig"}d). The lower expression level of JAG1 protein in p53KO than in Wt was concordant with the results of qRT‐PCR analysis (Fig. [5](#cas13075-fig-0005){ref-type="fig"}c,d). Suppressed proliferation in Wt cells treated with siJAG1 compared with cells treated with siNON was evident 2 days after initiation of treatment (Fig. [5](#cas13075-fig-0005){ref-type="fig"}e). No obvious effect of siJAG1 on proliferation in p53 KO cells was observed (Fig. [5](#cas13075-fig-0005){ref-type="fig"}e).

Discussion {#cas13075-sec-0014}
==========

To our knowledge, this study is the first report of the prognostic significance of JAG1 expression in cancer cells in patients with CRC. Moreover, our data indicated a relationship between JAG1 and E‐cadherin expression in the prognosis of CRC. Furthermore, we provide novel insight into the correlation between KRAS status and JAG1 expression in CRC patients. Various studies previously reported that a high expression level of JAG1 was detected in cancer cells[16](#cas13075-bib-0016){ref-type="ref"}, [17](#cas13075-bib-0017){ref-type="ref"}, [18](#cas13075-bib-0018){ref-type="ref"}, [19](#cas13075-bib-0019){ref-type="ref"}, [24](#cas13075-bib-0024){ref-type="ref"} and was correlated with tumor grade in human patients.[18](#cas13075-bib-0018){ref-type="ref"} However, the prognostic significance of JAG1 expression in cancer cells of CRC has not been determined. Our study demonstrated that higher JAG1 expression in cancer cells of CRC patients is associated with a poorer survival rate and increased risk of recurrence and that combination of high JAG1 expression with low E‐cadherin expression leads to severely poor outcome.

Three causes of the poor survival rate and increased risk of recurrence associated with high JAG1 expression have been proposed: increased cell proliferation or maintenance of survival, acquisition of stem cell‐like phenotype and induction of an EMT‐like phenotype in cancer cells. Our study indicated that siRNA‐mediated *JAG1* gene silencing delayed cell proliferation, with a subsequent decrease in cell number, in a colon cancer cell line. Similar results have been reported previously.[18](#cas13075-bib-0018){ref-type="ref"}, [19](#cas13075-bib-0019){ref-type="ref"} Evidence from our *in vitro* study and previous reports support the poor prognostic significance of high JAG1 expression in CRC.

The second possibility involves JAG1 protein expression associated with endothelium. We found that high expression of JAG1 protein in endothelium was associated with high expression of JAG1 protein in cancer cells and a poor prognosis, especially an increased recurrence risk. This result may be associated with acquisition of a stem cell‐like phenotype in cancer cells through Notch pathway activation by JAG1 secreted from the endothelium in CRC, as described previously.[15](#cas13075-bib-0015){ref-type="ref"} While our study did not address to explore mechanisms of high JAG1 expression in endothelium, some mechanisms were speculated from previous reports.[25](#cas13075-bib-0025){ref-type="ref"}, [26](#cas13075-bib-0026){ref-type="ref"} Namely, proinflammatory cytokines such as TNF‐α and IL6 are possible inducer for JAG1 expression in endothelium. In addition, JAG1 upregulation in colon cancer cell lines induced by forced Notch pathway activation promotes stemness in the cancer cells themselves through positive feedback.[27](#cas13075-bib-0027){ref-type="ref"} Our study indicated that JAG1 expression in cancer cells was strongly correlated with JAG1 expression in endothelium and that a stronger intensity of JAG1 staining in endothelium and cancer cells was associated with poor prognosis. Namely, JAG1 secreted from endothelium stimulates Notch pathway in cancer cells, and JAG1 expression in cancer cells may be upregulated dependent on the activity of Notch pathway itself in cancer cells. Then, JAG1‐Notch signaling in cancer cells may be amplified through positive feedback. These findings might mean that the transition toward a cancer stem cell‐like phenotype in cancer cells is promoted thorough interaction between endothelium and cancer cells mediated by JAG1, leading to a poorer prognosis in CRC patients.

Our study also suggests the significance of the JAG1‐Notch pathway in EMT in human CRC. We detected a significant association between low E‐cadherin and high JAG1 expression in CRC clinical samples and found that high JAG1 expression in cancer cells of CRC correlated with histologic type (decreased differentiation status) and T stage (deep invasion) among clinicopathologic characteristics. This correlation may be caused by an EMT‐like phenomenon induced by JAG1‐Notch pathway activation. Induction of an EMT‐like phenotype in cancer cells might allow these cells to exit from their original site, migrate to distant locations, and survive in a new microenvironment.[28](#cas13075-bib-0028){ref-type="ref"}, [29](#cas13075-bib-0029){ref-type="ref"} It was reported that Notch signaling mediates EMT thorough upregulation of Snail protein.[30](#cas13075-bib-0030){ref-type="ref"} Moreover, forced Notch pathway activation was shown to increase JAG1 expression and promote EMT through positive feedback in a colorectal cancer cell line.[27](#cas13075-bib-0027){ref-type="ref"} Our *in vitro* study demonstrated that although siRNA‐mediated *JAG1* gene silencing induced the transition to a more epithelial phenotype, Wnt pathway activation by inhibition of GSK‐3β not only induced the transition to a more mesenchymal phenotype but also increased JAG1 expression, as predicted from circumstantial evidence reported previously.[16](#cas13075-bib-0016){ref-type="ref"}, [17](#cas13075-bib-0017){ref-type="ref"}, [24](#cas13075-bib-0024){ref-type="ref"}, [31](#cas13075-bib-0031){ref-type="ref"} Previous studies and our *in vitro* study support the significant role of JAG1‐Notch pathway activation in poor prognosis in human CRC through induction of EMT.

It was recently reported that concomitant Notch activation and p53 deletion triggers EMT and metastasis in a genetically engineered mouse model.[32](#cas13075-bib-0032){ref-type="ref"} We demonstrated that siJAG1 delayed or inhibited proliferation in the Wt cell line but had a less potent effect in the *p53* ^*−/−*^ cell line. Moreover, whereas siJAG1 increased expression of E‐cadherin and decreased Snail protein in the Wt cell line, a similar effect could not be detected in the *p53* ^*−/−*^ cell line (data not shown). These results may indicate that JAG1‐Notch signaling is important for induction of an EMT‐like phenotype as well as proliferation through suppression of a p53‐related pathway.[33](#cas13075-bib-0033){ref-type="ref"} Alternatively, lower expression of JAG1 mRNA and protein in the *p53* ^*−/−*^ cell line compared with Wt might indicate a reciprocal relationship between JAG1 protein expression and p53 status.[33](#cas13075-bib-0033){ref-type="ref"} This is an unexpected result, and our studies could not validate a model in which concomitant Notch activation and p53 deletion triggers EMT.[32](#cas13075-bib-0032){ref-type="ref"} To address this issue, the effect of exogenous treatment with JAG1 in *p53* ^*−/−*^ cancer cells should be examined in the future. In the aspect of low JAG1 expression induced by p53 KO, our preliminary analysis in human clinical specimens indicated that low JAG1 expression was significantly associated with the high proportion of loss of heterogeneity in p53 status (data not shown). Thus, future study of the association between JAG1 expression and p53 status in CRC patients might reveal the reciprocal relationship between p53 status and JAG1 expression.

Our findings also suggested that EMT is induced by mediators other than JAG1‐Notch signaling, as indicated by little correlation between the low staining intensity of E‐cadherin and high JAG1 expression. Consequently, we demonstrated an additive impact on prognosis of a combination of high JAG1 and low E‐cadherin expression, and the poorest survival rate for both OS and RFS was indicated for this combination. We could not find any association between JAG1 expression and clinicopathologic characteristics in groups stratified as low E‐cadherin expression, and, therefore, it might be important to identify which downstream pathway of JAG1‐Notch leads to poorer prognosis in these groups.

Our study indicated a shorter recurrence free interval after surgery in patients with high JAG1 expression among the subgroup with intensity 2/3 of E‐cadherin staining (Fig. [3](#cas13075-fig-0003){ref-type="fig"}), and showed that this phenomenon might be associated with a high rate of mutation in KRAS (Table [4](#cas13075-tbl-0004){ref-type="table-wrap"} and Fig. S7). It was previously reported that MEK inhibitor suppresses JAG1 expression induced by growth factors in head and neck squamous cell carcinoma.[34](#cas13075-bib-0034){ref-type="ref"} In our study, MEK inhibitor suppressed JAG1 expression as well as SNAIL expression and upregulated E‐cadherin in a colon cancer cell line that has a KRAS mutation and is predicted to have activation of the MAP kinase pathway.[35](#cas13075-bib-0035){ref-type="ref"} Therefore, activation of the MAP kinase pathway by KRAS mutation might be partially upstream of JAG1 expression in CRC.

While this study presented the novel finding of the association among high JAG1 expression, KRAS status and prognostic significance in CRC, there are some limitations of the present study, such as the retrospective study design, the sample size, the various stages, and the lack of information for molecular status. Multicenter prospective study that enable investigation of the large sample size possibly verify the validity of our findings in this study.

In conclusion, to our knowledge this is the first report demonstrating the poor prognostic significance of high JAG1 expression in CRC. Moreover, our study also revealed that low expression of E‐cadherin plays an additive role for poor prognosis associated with high JAG1 expression in CRC. The results of our *in vitro* study support the poor prognostic impact associated with high JAG1 expression in CRC and suggest the clue of potential mechanisms for the complicated regulation of JAG1 expression and JAG1‐Notch pathway‐induced cancer development, as shown by the model illustrated in Figure [6](#cas13075-fig-0006){ref-type="fig"}. Furthermore, this study implicates JAG1 and its related signaling as a potential target for the development of new therapeutic approaches to reduce recurrence risk and cancer death after surgery for CRC.

![Hypothesized mechanisms of cancer recurrence or death induced by JAG1‐Notch pathway activation following increased JAG1 expression regulated by various factors.](CAS-107-1705-g006){#cas13075-fig-0006}
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**Fig. S1.** Verification of anti‐JAG1 antibody for immunohistochemical staining to analyze the prognostic value of JAG1 expression in human CRC.

**Fig. S2.** Comparison between anti‐JAG1 antibodies for immunohistochemical staining in human CRC.

**Fig. S3.** Prognostic significance of JAG1 expression in CRC cancer cells in all patients and patients with stage 0--III disease.

**Fig. S4.** Prognostic significance of JAG1 expression in endothelium by analysis of Kaplan--Meier estimates and Cox proportional hazards model.

**Fig. S5.** Representative immunohistochemical staining of E‐cadherin expression in human CRC tissues.

**Fig. S6.** Prognostic significance of E‐cadherin expression by analysis of Kaplan--Meier estimates.

**Fig. S7.** Correlation between KRAS status and JAG1 expression in CRC patients with staining intensity 2/3 for E‐cadherin expression.

**Fig. S8.** Effect of inhibition of RAS‐MEK‐MAP kinase pathway on JAG1, SNAIL and E‐cadherin protein level in the cancer cell lines HCT‐116 and Caco‐2.

**Fig. S9.** Effect of JAG1 gene silencing on epithelial--mesenchymal transition in the cancer cell line HCT‐116.

**Table S1.** JAG1 expression in cancer cells stratified by E‐cadherin expression (based on proportion of positive staining) and correlation with clinicopathologic characteristics, JAG1 expression in endothelium, and KRAS status.
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